Polymeric nano/microparticles for oral delivery of proteins and peptides

Biomaterials Fabrication and Processing Handbook

Volumn , Issue , 2008, Pages 171-192

  Sajeesh, S ^a   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904752895     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (141)

1. Walsh, G. Pharmaceutical biotechnology products approved within the European union. Eur. J. Pharm. Biopharm., 55, 3, 2003.
2. Mcmartin, C. Pharmacokinetics of peptides and proteins: opportunity and challenges. Adv. Drug Del. Rev., 22, 39, 1992.
3. Humphrey, M.J., Ringrose, P.S. Peptides and related drugs: a review of their absorption, metabolism and excretion. Drug Met. Rev., 17, 283, 1986.
4. Meibohm, B. Pharmacokinetics of protein- and nucleotide-based drugs. In Biomaterials for Delivery and Targeting of Proteins and Nucleic Acid. Mahato, R.I. (Ed.) CRC Press, USA, 2005, 275.
5. Ingemann, I. et al. Peptide and protein drug delivery systems for non-parenteral routes of administration. In Pharmaceutical Formulation Development of Peptides and Proteins. Frokjaer, S. and Hovgaard, L. (Eds.) Taylor & Francis, London, 2000, 189.
6. Edman, P., Bjork, E. Nasal delivery of peptide drugs. Adv. Drug Del. Rev., 8, 165, 1992.
7. Sood, A., Panchagnula, P. Peroral route: an opportunity for protein and peptide drug delivery. Chem. Rev., 101, 3275, 2001.
8. Fix, J.A. Oral controlled release technology for peptides: status and future prospects. Pharm. Res., 13, 1760, 1996.
9. Schen, W.C. Oral peptide and protein delivery: unfulfilled promises? Drug Dis. Tod., 8, 607, 2003.
10. Lee, V.H.L., Yamamoto, Y. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Del. Rev., 4, 171, 1990.
11. Woodley, J.F. Enzymatic barriers for GI peptides and protein delivery. Cric. Rev. Ther. Drugs, 11, 61, 1994.
12. Zhou, X.H. Overcoming enzymatic and absorption barriers to non-parentally administrated protein and peptide drugs. J. Con. Rel., 29, 239, 1994.
13. Tandon V.R. P-glycoprotein: pharmacological relevance. Ind. J. Pharmacol., 38, 13, 2006.
14. Fanaso, A. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci., 87, 1351, 1998.
15. Saffran, M. et al. A new approach to the oral administration of insulin and other peptide drugs. Science, 233, 1081, 1986.
16. Gomez-Orellana, I. Strategies to improve oral drug bioavailability. Expert Opin., 2, 119, 2005.
17. Bernkop-Schnurch, A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administrated therapeutic peptides and proteins. J. Con. Rel., 52, 1, 1998.
18. Ward, P.D., Tippin, T.K., Thakker, D.R. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Tech. Tod., 3, 346, 2000.
19. Daugherty, A.L., Mrsny, R.J. Regulation of the intestinal epithelial paracellular barrier. Pharm. Sci. Tech. Today, 2, 281, 1999.
20. Aungst, B.J. Intestinal permeation enhancers. J. Pharm. Sci., 89, 429, 2000.
21. Mesiha, M.S., Ponnapula, S., Plakogiannis, F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and α-tocopherol dispersions. Int. J. Pharm., 249, 1, 2002.
22. Aungst, B.J. et al. Enhancement of the intestinal absorption of peptides and non-peptides. J. Con. Rel., 41, 19, 1996.
23. Anderberg, E.K., Nystrom, C., Artusson, P. Epithelial transport of drugs in cell culture VII: effects of pharmaceutical surfactants excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (caco-2) cells. J. Pharm. Sci., 81, 879, 1992.
24. Katre, N.V. The conjugation of proteins with poly(ethylene glycol) and other polymers altering properties of proteins to enhance their therapeutic potential. Adv. Drug Del. Rev., 10, 91, 1993.
25. Allémann, E., Leroux, J.C., Gurny, R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Del. Rev., 34, 171, 1998.
26. Couvreur, P., Dubernet, C., Puisieux, F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm., 41, 2, 1995.
27. Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Con. Rel., 70, 1, 2001.
28. Junga, T. et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm., 50, 147, 2000.
29. Florence, A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res., 14, 259, 1997.
30. Junginger, H.E., Verhoef, J.C. Macromolecules as safe penetration enhancers for hydrophilic drugs-a fiction? Pharm. Sci. Tech. Tod., 1, 370, 1998.
31. Florence, A.T. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Dis. Tod. Tech., 2, 75, 2005.
32. Delie, F., Blanco-Príeto, M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules, 10, 65, 2005.
33. Florence, A.T. Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target, 12, 65, 2004.
34. Rubas, W., Grass, G.M. Gastrointestinal lymphatic absorption of peptides and proteins. Adv. Drug Del. Rev., 7, 15, 1991.
35. Volkheimer, G., Persorption von mikropartikeln, Pathologe, 14, 247, 1993.
36. Shakweh, M. et al. Particle uptake by Peyer’s patches; a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv., 1, 141, 2004.
37. Hussain, N. et al. Recent advances in the understanding of uptake of micro particulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev., 50, 107, 2001.
38. Clark, M.A., Jepson, M.A., Hirst, B.H. Exploiting M cells for drug and vaccine delivery. Adv. Drug Del. Rev., 50, 81, 2001.
39. Ermak, T.H., Giannasca, P.J. Microparticle targeting to M cells. Adv. Drug Deliv. Rev., 34, 261, 1998.
40. Florence, A.T., Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev., 50, S69, 2001.
41. Brayden, D. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci., 14, 183, 2001.
42. Wasan, K.M. The role of lymphatic transport in enhancing oral protein and peptide. Drug Del. Ind. Pharm., 28, 1047, 2002.
43. Jani, P., Halbert, G.W., Langridge, J., Florence, A.T. The uptake and translocation of latex nanospheres and microspheres after oral administer to rats. J. Pharm. Pharmacol., 41, 809, 1989.
44. Jani, P. et al. Nanoparticle uptake by the rat gastro-intestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol., 42, 821, 1990.
45. Desai, M.P., Labhasetwar, V., Amidon, G.L., Levy, R.J. Gastrointestinal uptake of biodegradable microparticles:effect of particle size. Pharm. Res., 13, 1838, 1996.
46. Shakweh, M., Besnard, M., Nicolas, V., Fattal, E. Poly(lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer’s patches in mice. Eur. J. Pharm. Biopharm., 61, 1, 2005.
47. Ermak, T.H. et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer’s patch M cells. Cell Tissue Res., 279, 2, 1995.
48. Sahoo, S.K., Panyam, J., Prabha, S., Labhasetwar, V. Residual polyvinyl alcohol associated with poly(d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Con. Rel., 82, 105, 2002.
49. Jepson, M.A., Simmons, N.L., Hagan, D.T.O., Hirst, B.H. Comparison of poly(dl-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells, J. Drug Targ., 1, 245, 1993.
50. Jepson, M.A., Clark, M.A., Hirst, B.H.M. Cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv. Drug Del. Rev., 56, 511, 2004.
51. Hussain, N., Jani, P., Florence, A.T. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res., 14, 613, 1997.
52. Sinha, V.R., Tehran, A. Biodegradable microsphere for protein delivery, J. Con. Rel., 90, 261, 2003.
53. Weert, M.V., Hennink, W.E., Jiskoot, W. Protein instability in poly(lactic-co-glycolic acid) nanoparticles. Pharm. Res., 17, 1159, 2000.
54. Ibrahim, M.A., Ismail, A., Fetouh, M.I., Gopferich, A. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Con. Rel., 106, 241, 2005.
55. Owens, D.E., Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 307, 93, 2006.
56. Carstensen, H., Muller, R.H., Muller, B.W. Particle-size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model-drug carriers as parameters related to RES uptake. Clin. Nutr., 11, 289, 1992.
57. Mathiowitz, E. et al. Biologically erodable microspheres potential oral drug delivery systems, Nature, 386, 410, 1997.
58. Chickering, D., Jacob, J., Mathiowitz, E. Poly(fumaric-co-sebacic) microspheres as oral drug delivery systems, Biotechnol. Bioeng., 52, 96, 1996.
59. Damge, C., Vranckx, H., Balschmidt, P., Couvreur, P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci., 86, 1997, 1403.
60. Watnasirichaikul, S., Rades, T., Tucker, I.G., Davies, N.M. In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol., 54, 473, 2002.
61. Radwan, M.A. Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats. Drug Del. Int. Pharm., 9, 981, 2001.
62. Damge C., Maincent P., Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Con. Rel. 2006 published online Oct 25.
63. Pan, Y. Study on preparation and oral efficacy of insulin-loaded poly(lactic-co-glycolic acid) nanoparticles. Yao Xue Xue Bao., 37, 374, 2002.
64. Cui, F. et al. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery:preparation, in vitro characterization and in vivo evaluation. J. Con. Rel., 114, 242, 2006.
65. Akiyama, Y., Nagahara, N. Novel formulation approaches to oral mucoadhesive drug delivery systems. In Bioadhesive Drug Delivery Systems-Fundamentals, Novel Approaches and Development, Mathiowitz, E., Chickering, D.E., Lehr, C.M. (Eds.) Marcel Dekker, New York, 1998, 477.
66. Vasir, J.K., Tambwekar, K., Garg, S. Bioadhesive microspheres as a controlled drug delivery system. Int. J. Pharm., 255, 13, 2003.
67. Lehr, C.M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Cri. Rev. Ther. Drug Carrier Sys., 11, 119, 1994.
68. Chowdary, K.P., Rao, Y.S. Mucoadhesive microspheres for controlled drug delivery. Bio. Pharm. Bull., 27, 1717, 2004.
69. Huang, Y., Leobandung, W., Foss, A., Peppas, N.A. Molecular aspects of muco and bioadhesion: tethered structures and site-specific surfaces. J. Con. Rel., 65, 63, 2000.
70. Ahuja, A., Khar, R.K., Ali, J. Mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm., 23, 489, 1997.
71. Dodou, D., Breedveld, P., Wieringa, P.A. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur. J. Pharm. Biopharm., 60, 1, 2005.
72. Peppas, N.A., Sahlin, J.J. Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials, 17, 1553, 1996.
73. Lowman, A.M., Peppas, N.A. Hydrogels. In Enclyopedia of Controlled Drug Delivery, Vol. 1, Mathiowitz, E. (Ed.) John Wiley & Sons Inc., New York, 1999, 397.
74. Haas, J., Lehr, C.M. Developments in the area of bioadhesive drug delivery systems. Expert Opin. Bio. Ther., 2, 287, 2002.
75. Leung, S.-H.S., Robinson, J.R. The contribution of anionic polymer structural features to mucoadhesion. J. Con. Rel., 5, 223, 1988.
76. Gu, J.M., Robinson, J.R., Leung, S.H. Binding of acrylic polymers to mucin/epithelial surfaces:structure-property relationships. Crit. Rev. Ther. Drug Carrier Sys., 5, 21, 1988.
77. Park, H., Robinson, J.R. Mechanism of mucoadhesion of PAA hydrogels. Pharm. Res., 4, 457, 1987.
78. Bernkop-Schnurch, A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm., 194, 1, 2000.
79. Blanchette, J., Kavimandan, N., Peppas, N.A. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacotherapy, 58, 142, 2004.
80. Peppas, N.A., Klier, J. Controlled release by using poly(methacrylic acid-g-ethylene glycol) hydrogels. J. Con. Rel., 16, 203, 1991.
81. Ascentiis, A.D., Degrazia, J.L., Bowman, C.N., Colombo, P., Peppas, N.A. Mucoadhesion of P (2-HEMA) is improved when linear PEO chains are added to polymer networks. J. Con. Rel., 33, 197, 1995.
82. Peppas, N.A., Kuys, K.B., Torres-Lugo, M., Lowman, A.M. PEG containing hydrogels in drug delivery. J. Con. Rel., 62, 81, 1999.
83. Leitner, V.M., Walker, G.F., Bernkop-Schnurch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm., 56, 207, 2003.
84. Greindl, M., Bernkop-Schnurch, A. Development of a novel method for the preparation of thiolated polyacrylic acid nanoparticles. Pharm. Res., 23, 2183, 2006.
85. Bernkop-Schnurch, A., Weithaler, A., Albrecht, K., Greimel, A. Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm., 317, 76, 2006.
86. David, J., Brayden, D.J. O’Mahony, D.J. Novel oral drug delivery gateways for biotechnology products:polypeptides and vaccines. Pharm. Sci. Tech. Tod., 2, 67, 1998.
87. Anderson, J.M., Balda, M.S., Fanning, A.S. The structure and regulation of tight junctions. Curr. Opin. Cell Bio. Suppl., 5, 772, 1993.
88. Borcharel, G. et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug abs. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Con. Rel., 39, 131, 1996.
89. Luessen, H.L. et al. Mucoadhesive polymers in peroral peptide drug delivery. IV polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosa in vitro. J. Con. Rel., 45, 15, 1997.
90. Luessen, H.L. et al. Mucoadhesive polymers in peroral peptide drug delivery. II carbomer and poly carbophil are potent inhibitors of intestinal proteolytic enzyme trypsin. Pharm. Res., 12, 129, 1995.
91. Artursson, P., Ungell, A.L., Löfroth, J.E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res., 10, 1123, 1993.
92. Rubas, W. et al. Flux measurements across caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci., 85, 165, 1996.
93. Kriwet, B., Kissel, T. Poly(acrylic acid) microparticles widen the intercellular spaces of caco-2 cell monolayers: examination by confocal laser scanning microscopy. Eur. J. Pharm. Biopharm., 42, 233, 1996.
94. Ichikawa, H., Peppas, N.A. Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using caco-2 cell monolayers. J. Biomed. Mat. Res., 67, 609, 2003.
95. Torres-Lugo, M., Garcia, M., Record, R., Peppas, N.A. pH sensitive hydrogels as GI tract absorption enhancers: transport mechanism of salmon calcitonin and other model molecules using caco-2 cell model. Biotech. Prog., 18, 612, 2002.
96. Torres-Lugo, M., García, M., Record, R., Peppas, N.A. Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins. J. Con. Rel., 80, 197, 2002.
97. Ranjha, N.M., Doelkar, M. pH sensitive hydrogels for site specific delivery. I. swelling behavior of crosslinked copolymers of acrylic acid and methacrylic acid. S.T.P Pharm. Sci., 9, 335, 1999.
98. Lowman, A.M. et al. Oral delivery of insulin using pH responsive complexation gels. J. Pharm. Sci., 88, 933, 1999.
99. Foss, A.C., Goto, T., Morishita, M., Peppas, N.A. Development of acrylic-based copolymers for oral insulin delivery. Eur. J. Pharm. Biopharm., 57, 163, 2004.
100. Morishita, M. et al. Novel oral insulin delivery systems based on complexation polymer hydrogels:single and multiple administration studies in type 1 and 2 diabetic rats. J. Con. Rel., 110, 587, 2006.
101. Morishita, I. et al. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm., 78, 9, 1992.
102. Hosny, E.A., Al-Shora, H.I., Elmazar, M.M.A. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int. J. Pharm., 237, 71, 2002.
103. Jain, D., Panda, A.K., Majumdar, D.K. Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharm. Sci. Tech., 6, E100, 2005.
104. Paul, W., Sharma, C.P. Chitosan, A drug carrier for 21st century: a review. STP Pharm. Sci., 10, 5, 2000.
105. Rao, S.B., Sharma, C.P. Use of chitosan as a biomaterial: studies on its safety and haemostatic potential. J. Biomat. Mat. Res., 34, 21, 1997.
106. Berger, J. et al. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur. J. Pharm. Biopharm., 57, 35, 2004.
107. Kas, H.S. Chitosan: properties, preparations and application to microparticulate systems. J. Microencap., 14, 689, 1997.
108. Agnihotri, S., Mallikarjuna, N.N., Aminabhavi, T.M. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J. Con. Del., 100, 5, 2004.
109. Illum, L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res., 15, 1326, 1998.
110. Thanou, M., Verhoef, J.C., Junginger, H.E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Del. Rev., 50, S91, 2001.
111. Schipper, N.G.M. et al. Chitosan as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res., 14, 923, 1997.
112. Artursson, P., Lindmark, T., Davis, S.S., Illum, L. Effect of chitosan on the permeability of monolayer of intestinal epithelial cells (caco-2). Pharm. Res., 11, 1358, 1994.
113. Ma, Z., Lim, L.Y. Uptake of chitosan and associated insulin in caco 2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res., 20, 1812, 2003.
114. Kotze, A.F. et al. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces:in vitro evaluation in intestinal epithelial cells (caco-2). Pharm. Res., 14, 1197, 1997.
115. Thanou, M. et al. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (caco-2 cells) and in vivo (rats) Pharm. Res., 17, 27, 2000.
116. Prego, C., Torres, D., Alonso, M.J. Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behavior and in vivo effectiveness. Nanosci. Nanotechnol., 6, 2921, 2006.
117. Pan, Y. et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm., 249, 139, 2002.
118. Tozaki, H. et al. Chitosan capsules for colon drug delivery: improvement of insulin absorption from rat colon, J. Pharm. Sci., 86, 1016, 1997.
119. Lubben, I.M.V. et al. Chitosan microparticles for oral vaccination: preparation characterization and preliminary in vivo uptake studies in murine payer’s patches. Biomaterials, 22, 687, 2001.
120. Tønnesen, H.H., Karlsen, J. Alginate in drug delivery systems. Drug Dev. Ind. Pharm., 28, 621, 2002.
121. Gombotzb, W.R., Wee, S.W. Protein release from alginate matrices. Adv. Drug Del Rev., 31, 267, 1998.
122. Liu, P., Krishnan, T.R. Alginate-pectin-poly-l-lysine particulate as a potential controlled release formulation. J. Pharm. Pharmcol., 51, 141, 1999.
123. Hari, P.R., Chandy, T., Sharma, C.P. Chitosan/calcium alginate beads for oral delivery of insulin. J. Appl. Pol. Sci., 59, 1795, 1996.
124. Dileep, K.J., Roswen M.L., Sharma, C.P. Modulation of insulin from chitosan/alginate microspheres. Trends Biomat. Art. Organs, 12, 42, 1998.
125. Jerry, N., Anitha, Y., Sharma, C.P., Sony, P. In vivo absorption studies from an oral delivery system. Drug Del., 8, 19, 2001.
126. Kim, B.Y., Jeong, J.H., Park, K., Kim, J.D. Bioadhesive interaction and hypoglycemic effect of insulinloaded lectin-microparticle conjugates in oral insulin delivery system. J. Con. Rel., 102, 525, 2005.
127. Ramdas, M. et al. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats. J. Microencap., 17, 405, 2000.
128. Morcol, T. et al. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm., 277, 91, 2004.
129. Arshady, R. Manufacturing methodology of microspheres. In Microspheres, Microcapusles and Liposomes Vol 1: Preparation and Chemical Applications, Arshady, R. (Ed.) Citus Book, U.K., 1999, 85.
130. De Jacghere, F., Doelkar, E., Gurny, R. Nanoparticles. In Encyclopedia of Controlled Drug Delivery Vol II, Mathowitz, E. (Ed.) John Wiley & Sons Inc. New York, 1999, 641.
131. Barratt, G. et al. Polymeric micro- and nanoparticles as drug carriers. In Polymeric Biomaterials, second edition, Dumitriu, S. (Ed.) Marcel Dekker, New York, 2002, 753.
132. Mathiwotiz, E., Kreitz, M.R., Peppas, L.-B. Microencapsulation. In Encyclopedia of Controlled Drug Delivery Vol II, Mathowitz, E. (Ed.) John Wiley & Sons Inc. New York, 1999, 493.
133. Allémann, E., Gurny, R., Doelker, E. Drug loaded nanoparticles-preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm., 39, 173, 1993.
134. Donini, C., Robinson, D.N., Colombo, P., Giordano, F., Peppas, N.A. Preparation of poly(methacrylic acid-g-poly(ethylene glycol))nanospheres from methacrylic monomers for pharmaceutical applications. Int. J. Pharm., 245, 83, 2002.
135. Skovby, M.H.B., Kops, J. Preparation by suspension polymerization of porous beads for enzyme immobilization. J. Appl. Pol. Sci., 39, 169, 1990.
136. Keiwet, B., Walker, E., Kissel, T. Synthesis of bioadhesive of poly(acrylic acid) nano and microparticles using an inverse emulsion polymerization method for entrapment of hydrophilic drug candidates. J. Con. Rel., 56, 149, 1998.
137. Sajeesh, S., Sharma, C.P. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm., 325, 147, 2006.
138. Sajeesh, S., Sharma, C.P. Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery. J. Biomed Mat. Res: Appl. Biomat., 76B, 298, 2006.
139. Sajeesh, S., Sharma C.P. Novel polyelectrolyte complex microparticles based on polymethacrylic acidpolyethylene glycol for oral peptide delivery. J. Biomat. Sci.: Polym. Edn., 18, 1125, 2007.
140. Sajeesh, S., Sharma, C.P. Interpolymer complex microparticles based on polymethacrylic acid-chitosan for oral insulin delivery. J. Appl. Pol. Sci., 99, 506, 2006.
141. RaviKumar, M.N.V. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharmceut. Sci., 3, 234, 2000.